Episodes 31-45 of 258
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
MinuteCE®Immunotherapy-Based Approaches for First-Line Treatment of Advanced HCC: The Evidence
Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
MinuteCE®Applying Current Guidelines in the First-Line Treatment of MSI-H/dMMR mCRC—A Case Discussion
Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
MinuteCE®Clinical Implications of Current Guidelines on First-Line Immunotherapy and PARP Inhibitors for TNBC
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®The Evolving Treatment Landscape for MBC: Emerging Therapies
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
MinuteCE®Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
MinuteCE®Immunotherapy for TNBC in the Perioperative Setting: Clinical Evidence and Considerations
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®Management of HER2-Low MBC Following First-Line Disease Progression
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
MinuteCE®Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®Expert Viewpoint: Optimizing Breast Cancer Treatment
Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
MinuteCE®Guideline Recommendations for the Definition and Treatment of HER2-Low Breast Cancer
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
MinuteCE®Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
